Fig. 2. Seven-day point prevalence of biochemically confirmed abstinence for varenicline versus  placebo using intention to treat analysis. The 7-day point prevalence of abstinence at 3, 6, and 12 months was higher for varenicline versus  placebo. *P < 0.05.

Fig. 2. Seven-day point prevalence of biochemically confirmed abstinence for varenicline versus  placebo using intention to treat analysis. The 7-day point prevalence of abstinence at 3, 6, and 12 months was higher for varenicline versus  placebo. *P < 0.05.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal